[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100508165":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":26,"centralContacts":30,"locations":35,"responsibleParty":49,"collaborators":21,"id":52,"slug":53,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":54,"sex":60,"minAge":61,"maxAge":21,"enrollmentInfo":62,"targetDuration":21,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":21,"overallStatus":37,"whyStopped":21,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"Samsung Medical Center","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Postoperative radiation therapy to breast \u002F chest wall and regional lymph node area","EXPERIMENTAL","Patient achieved complete response after neoadjuvant chemotherapy will receive postoperative radiation therapy with dose of 42.4 Gy in 16 fractions to whole breast \u002F chest wall and regional lymph node area. Internal mammary or supraclavicular lymph node area boost will be simultaneously delivered with total dose of 53.6 Gy in 16 fractions.\n\nPatient with partial response, stable disease, or progressive disease after neoadjuvant chemotherapy will receive postoperative radiation therapy with dose of 42.4 Gy in 16 fractions to whole breast \u002F chest wall and regional lymph node area. Internal mammary or supraclavicular lymph node area boost will be simultaneously delivered with total dose of 56.0 Gy in 16 fractions.",[13,14],"Radiation: Whole breast \u002F chest wall & regional lymph node irradiation","Radiation: Internal mammary or supraclavicular lymph node boost",[16,22],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":21},"RADIATION","Whole breast \u002F chest wall & regional lymph node irradiation","Whole breast \u002F chest wall and corresponding regional lymph node irradiation with dose of 42.4 Gy in 16 fractions",[9],null,{"type":17,"name":23,"description":24,"armGroupLabels":25,"otherNames":21},"Internal mammary or supraclavicular lymph node boost","Simultaneous boost to Internal mammary or supraclavicular lymph node area with dose of total 53.6 Gy or 56.0 Gy in 16 fractions, depending on the response after neoadjuvant chemotherapy",[9],[27],{"name":28,"affiliation":5,"role":29},"Haeyoung Kim, MD, PhD","PRINCIPAL_INVESTIGATOR",[31],{"name":28,"role":32,"phone":33,"phoneExt":21,"email":34},"CONTACT","82-2-3410-2612","haeyoung0131.kim@samsung.com",[36],{"facility":5,"status":37,"city":38,"state":21,"zip":39,"country":40,"countryCode":21,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"RECRUITING","Seoul","06351","South Korea",{"type":42,"coordinates":43},"Point",[44,45],126.9784,37.566,{"lat":45,"lon":44},[48],{"name":28,"role":32,"phone":33,"phoneExt":21,"email":34},{"type":29,"investigatorFullName":50,"investigatorTitle":51,"investigatorAffiliation":5,"oldNameTitle":21,"oldOrganization":21},"Haeyoung Kim","Associate professor","100508165","radiotherapy-dose-adaptation-based-on-tumor-biology-in-patients-with-cn2b-n3-breast-cancer-100508165",false,"NCT05896865","Radiotherapy Dose Adaptation Based on Tumor Biology in Patients With cN2b-N3 Breast Cancer","Radiotherapy Dose Adaptation Based on Tumor Biology in Patients With cN2b-N3 Breast Cancer: Non-randomized Phase II, Prospective Single Arm Study Clinical Trial","RADAPT-N3","Inclusion Criteria:\n\n* Female with age 19 or older\n* Metastasis to internal mammary and\u002For supraclavicular lymph nodes, assessed by radiological exams and\u002For biopsy\n* Underwent neoadjuvant chemotherapy\n* Pathologic confirmation of invasive breast cancer treated with breast conserving surgery or mastectomy\n* Eastern Cooperative Oncology Group performance status 0-2\n* Informed consent\n\nExclusion Criteria:\n\n* Previous history of radiation therapy to the chest\n* Distant metastasis","FEMALE","19 Years",{"count":63,"type":64},120,"ESTIMATED","INTERVENTIONAL",[67],"NA","The purpose of the study is to evaluate treatment outcomes of breast cancer with internal mammary or supraclavicular lymph node metastasis according to total radiation dose of postoperative radiation therapy differentiated by tumor response to neoadjuvant chemotherapy.\n\nThe main questions it aims to answer are:\n\n* 5-year disease-free survival\n* 5-year overall survival\n* 5-year locoregional recurrence\n* Adverse events after radiation therapy\n* Quality of life\n\nParticipants will be assessed by multi-dimensional methods before and after radiotherapy:\n\n* Disease status evaluation including physical and radiological examination\n* Quality of life assessment with questionnaires (BREAST-Q)\n* Adverse event assessment according to CTCAE version 5.0",[70],"Breast Cancer Stage III","2025-06-27",{"date":73,"type":74},"2025-06-29","ACTUAL",{"date":76,"type":74},"2023-03-16",{"date":78,"type":64},"2030-03-16",{"name":5,"class":6},1]